Systematic Reviews
Copyright ©The Author(s) 2023.
World J Meta-Anal. Jun 18, 2023; 11(5): 181-195
Published online Jun 18, 2023. doi: 10.13105/wjma.v11.i5.181
Table 1 Methodological aspects: General characteristics on the studies included
Ref.
Journal
Country
Study designs
Study analysis time
Objective
Kim et al[15], 2021British Journal of HaematologyKoreaRetrospective2009-2020To analyze genetic abnormalities in JMML to evaluate the genetic profile of this rare paediatric leukaemia in a single Korean institution
Hong et al[16], 2022Transplan tation and Cellular TherapyKoreaRetrospective comparative2013-2020To compare outcomes in children and adolescents with high-risk acute leukemia after a busulfan-based myeloablative conditioning regimen along with HRD HSCT with PT-Cy or MUD HSCT
Bertaina et al[17], 2018BloodItalyRetrospective2010-2015To report the outcome of children with acute leukemia who received either UD-HSCT or αβhaplo-HSCT
Bai et al[18], 2020Leukemia ResearchChinaRetrospective2008-2018To investigate the clinical characteristics, outcomes, and effects of HSCT (especially haplo-HSCT) among non- infant children with t(v;11q23)/MLL-r B-ALL
Ruggeri et al[19], 2021Transplan tation and Cellular TherapyItalyProspective cohort2011-2019To analyze the outcomes of unmanipulated haploidentical Transplantation using PT-Cy in pediatric patients with acute lymphoblastic leukemia
Sun et al[20], 2015European Review for Medi cal Pharmaco logical SciencesChinaRetrospective2002-2012To discuss the effect of transplantation and the difference in treatment effect among children having different donor patterns, aiming to identify the prognostic factors
Sano et al[21], 2021Frontiers in pediatricsJapanRetrospective2009-2019To aimed to evaluate the efficacy of T-cell replete HLA-HSCT for pediatric RR-BCP-ALL
Paina et al[22], 2018Cellular Therapy and TransplantationGermanyProspective cohort2006-2016To assess efficiency of haplo-HSCT performed with non-manipulated grafts of children and adolescents with high-risk acute leukemias. In this respect an efficiency study of haploidentical GVHD was performed at our clinic in children and adolescents with high-risk ALL and AML, at maximal observation terms of 10 years
Mo et al[23], 2016Internatio nal Journal of CancerChinaRetrospective comparative2011-2015To compare the therapeutic effects of single UCBT and unmanipulated haplo-HSCT in high-risk ALL children
Wang et al[24], 2020Journal of Internatio nal Clinical Cytometr y SocietyChinaProspective cohort2011-2016To determine the impact of pre- and post-MRD status as well as peri-transplant MRD kinetics on clinical outcomes focused on children with ALL who received haploidentical allografts
Zhang et al[25], 2022Chinese Medical JournalChinaRetrospective comparative2012-2018To explore the effect of allo- HSCT (especially haploidentical HSCT) on improving survival and reducing relapse for high-risk childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT
Zheng et al[26], 2020Cancer Communi cationsChinaRetrospective comparative2013-2017To compare the survival outcomes between high-risk AML children who underwent either unmanipulated HID-SCT or ISD-SCT at three large Chinese SCT centers
Trujillo et al[27], 2021American Society For Transplan tation and Celular TherapyColombiaRetrospective2012-2017To decrease the toxicity associated with the addition of 100 mg/kg of cyclophosphamide to a myeloablative regimen while maintaining a good antileukemic effect and a good engraftment rate, using an intermediate-intensity regimen
Yang et al[28], 2022HematologyChinaRetrospective2015-2021To investigate the outcomes and prognostic factors of pediatric AML patients with KMT2A rearrangements who were treated at our institution over a 5-year period
Bai et al[29], 2022BMC cancerChinaRetrospective2014-2019To explore the role of allo- HSCT (especially haploidentical-HSCT) in the treatment of paediatric patients with MLL-r AML in CR1 and investigated the prognostic factors of these patients
Miyamura et al[30], 2019Leukemia ResearchJapanRetrospective1988-2011To investigate the outcomes and prognostic factors of AML with KMT2A rearrangement treated with allogeneic HSCT
Oevermann et al[32], 2014BloodGermanyRetrospective comparative1996-2013To analyze the influence of KIR haplotypes on the outcome of children with ALL given haploidentical HSCT
Pérez-Martínez et al[33], 2020American Journal of Hematolo gySpainRetrospective1999-2016To compare and analyze the feasibility and outcome of a Spanish cohort of 2 haplo-HSCT platforms in children and adolescents with high-risk hematological malignancies: PT-Cy and ex vivo TCD grafts
Table 2 Characteristics of haploidentical transplants identified in the studies included
Ref.
All patients, n
Age, yr, median
Sex, male, n
Condition clinic
Haplo transplant cohort, n
Age, yr, median
Sex, male, n
Source of stem cells
Kim et al[15], 2021241.20115JMML14NRNRPBSC
Hong et al[16], 202280NR51ALL, AML, MPAL, and NK cell leukemia357.0022PBSC
Bertaina et al[17], 20183433.30210ALL, AML986.6065PBSC5 BM
Bai et al[18], 20203834.0025MLL-r B-ALL1944.0013NR
Ruggeri et al[19], 20211809.25114ALL1809.25114PBSC BM
Sun et al[20], 201511110.0073AML, ALL, CML, and MLL11110.0073PBSC BM
Sano et al[21], 20211910.0012RR-BCP-ALL1910.0012PBSC, PB + BM
Paina et al[22], 20181067.0065ALL, AML1067.0065BM + PBSC BM
Mo et al[23], 2016129NR42HR, ALL6510.0033G-BM, G-PB
Wang et al[24], 202016615.00114B-ALL and T-ALL16615.00114NR
Zhang et al[25], 20227411.0052HR T-ALL27212.0021BM
Zheng et al[26], 202082NR56HR AML6912.0042PBSC, BM
Trujillo et al[27], 20214211.0024ALL, AML, JMML, and CML4211.0024PBSC
Yang et al[28], 202221NR15AML, KMT2A rearrangents176.0612NR
Bai et al[29], 2022449.0025MLL-r AML37NRNRNR
Miyamura et al[30], 2019903.0049AML KMT2A rearrangents10NRNRNR
Oevermann et al[32], 20148510.00NRALL8510.00NRPBSC
Pérez-Martínez et al[33], 20201928.60118ALL, AML, MDS, JMML, CML, and biphenotyipic1928.60118PBSC BM
Table 3 Conditioning, event-free survival and overall survival of the analyzed patients
Ref.Haplo transplant cohort, nConditioning regimens (all cohorts)
Haplo cohort
IIIIIIIVEFS (%)OS (%)
Kim et al[15], 202114MAC: Bu-FluMAC: Bu-Flu-TBIRIC: Bu-Flu-TBI-NRSNRS
Hong et al[16], 202235MAC, Bu, FluMAC, Bu, Flu, and CyTBI after blinatumomab-74.4% (3 years)88.6% (3 years)
Bertaina et al[17], 201898MAC: BuMAC/TBI: TBI-basedTreosulfan based-62.0% (5 years)68.0% (5 years)
Bai et al[18], 2020181, 087MAC/chemo: Cytarabine, Cy, Bu, and semustine---89.5% (4 years), NRS87.4% (4 years); 57.1% (4 years)
Ruggeri et al[19], 2021180MAC/chemoMAC/TBIRIC-38.5%2 (2 years); 65%3; 44%4, and 18.8%550.8% (2 years); 76.5%7; 61.2%7; (NRS)
Sun et al[20], 2015111MAC: Bu, cycytarabine, and Me-CCNUMAC/TBI Cy, cytarabine--79.2% (5 years)NR
R19MAC: Bu, Flu, and melphalan, TBI-basedMAC: Bu-basedRIC-42.1% (3 years)57.4% (3 years)
Paina et al[22], 2018106MAC: Bu, Cy, and LomustinMAC, Bu-fluMAC: TreosulfanRIC: Melphalan; RIC: BuNR33.3% (10 years); 64.7%; 18.1%, (10 years)6
Mo et al[23], 201665Cytarabine, Bu, Cy, and semustineTBIMAC: Bu-Flu CarmustineMAC: CyFlu-TBI71% (2 years)82.0% (2 years)
Wang et al[24], 2020166RIC: Cy, MTX, MMF---60.2% (100 d)60.8% (100 d)
Zhang et al[25], 202223MAC: Bu-Cy, hydroxyurea cytarabine, and methy---80.1% (5 years)81.0% (5 years)
Zheng et al[26], 202069Bu-Cy, cytarabine, semustineBu-Cy-Hu, cytarabine, semustine--72.9% (3 years)73.0% (3 years)
Trujillo et al[27], 202142RIC: Bu-Flu-TBIRIC: Flu-Mel-TBI--46% (3 years)56% (3 years)
Yang et al[28], 202217Cytarabine, Bu, and Cy Me-CCNUCytarabine, Bu-Cy--NRSNRS
Bai et al[29], 202237Cytarabine, Bu-Cy, and semustine---65.6% (3 years)73.0% (3 years)
Miyamura et al[30], 201910MAC, Bu-TBIRIC, NR--NRSNRS
Oevermann et al[32], 201485TBINon TBI--50.6%7 (5 years); 29.5%7 (5 years)NR
Pérez-Martínez et al[33]192Flu-Thiotepa-Mel or BuTLI or TBI--49.2% (2 years)55.1% (2 years)